Selective induction of tumor-associated antigens in murine pulmonary vasculature using double-targeted adenoviral vectors

Gene Therapy

Volumn 12, Issue 13, 2005, Pages 1042-1048

  Everts, M ^a   Kim Park, S A ^a   Preuss, M A ^a   Passineau, M J ^a   Glasgow, J N ^a   Pereboev, A V ^a   Mahasreshti, P J ^a,b   Grizzle, W E ^a   Reynolds, P N ^c   Curiel, D T ^a  

^a University of Alabama at Birmingham   (United States)

^b UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^c ROYAL ADELAIDE HOSPITAL   (Australia)

Author keywords

Adenovirus; Cancer; Targeting; Tumor associated antigens

Indexed keywords

ADAPTOR PROTEIN; ADENOVIRUS VECTOR; CARCINOEMBRYONIC ANTIGEN; COXSACKIE VIRUS AND ADENOVIRUS RECEPTOR; LUCIFERASE; TUMOR ANTIGEN; TUMOR MARKER; VASCULOTROPIN RECEPTOR 1;

ANIMAL EXPERIMENT; ANTIGEN EXPRESSION; ARTICLE; CANCER THERAPY; CONTROLLED STUDY; DRUG TARGETING; GENE EXPRESSION; GENE INDUCTION; GENE TARGETING; LIVER; LUNG; LUNG BLOOD VESSEL; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; REPORTER GENE; TRANSCRIPTION REGULATION; TRANSGENE; TRANSGENIC MOUSE; WILD TYPE;

ADENOVIRIDAE; ANIMALS; CARCINOEMBRYONIC ANTIGEN; EXTRACELLULAR MATRIX PROTEINS; GENE EXPRESSION; GENE TARGETING; GENE THERAPY; GENETIC VECTORS; IMMUNOHISTOCHEMISTRY; LIVER; LUCIFERASES; MICE; MICE, TRANSGENIC; PROMOTER REGIONS (GENETICS); PROTEINS; PULMONARY CIRCULATION; RECEPTORS, VIRUS; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-1;

ADENOVIRIDAE; ANIMALIA; MURINAE;

EID: 21744431697     PISSN: 09697128     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.gt.3302491     Document Type: Article

References (33)

1. Boerman OC, van Schaijk FG, Oyen WJ, Corstens FH. Pretargeted radioimmunotherapy of cancer: progress step by step. J Nucl Med 2003; 44: 400-411.
2. Wels W et al. Recombinant immunotoxins and retargeted killer cells: employing engineered antibody fragments for tumor-specific targeting of cytotoxic effectors. Cancer Immunol Immunother 2004; 53: 217-226.
3. Glasgow JN, Bauerschmitz GJ, Curiel DT, Hemminki A. Transductional and transcriptional targeting of adenovirus for clinical applications. Curr Gene Ther 2004; 4: 1-14.
4. Kruyt FA, Curiel DT. Toward a new generation of conditionally replicating adenoviruses: pairing tumor selectivity with maximal oncolysis. Hum Gene Ther 2002; 13: 485-495.
5. Hammarstrom S. The carcinoembryonic antigen (CEA) family: structures, suggested functions and expression in normal and malignant tissues. Semin Cancer Biol 1999; 9: 67-81.
6. Slamon DJ et al. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987; 235: 177-182.
7. Khalil MY, Grandis JR, Shin DM. Targeting epidermal growth factor receptor: novel therapeutics in the management of cancer. Expert Rev Anticancer Ther 2003; 3: 367-380.
8. Muders M et al. Studies on the immunogenicity of hCEA in a transgenic mouse model. Int J Colorectal Dis 2003; 18: 153-159.
9. McLaughlin PM et al. The epithelial glycoprotein 2 (EGP-2) promoter-driven epithelial-specific expression of EGP-2 in transgenic mice: a new model to study carcinoma-directed immunotherapy. Cancer Res 2001; 61: 4105-4111.
10. McClarrinon M et al. In vivo studies of gene expression via transient transgenesis using lipid-DNA delivery. DNA Cell Biol 1999; 18: 533-547.
11. Shayakhmetov DM, Li ZY, Ni S, Lieber A. Targeting of adenovirus vectors to tumor cells does not enable efficient transduction of breast cancer metastases. Cancer Res 2002; 62: 1063-1068.
12. Li ZY et al. Xenograft models for liver metastasis: relationship between tumor morphology and adenovirus vector transduction. Mol Ther 2004; 9: 650-657.
13. Ando K et al. CTL access to tissue antigen is restricted in vivo. J Immunol 1994; 153: 482-488.
14. Tallone T et al. A mouse model for adenovirus gene delivery. Proc Natl Acad Sci USA 2001; 98: 7910-7915.
15. Reynolds PN et al. Combined transductional and transcriptional targeting improves the specificity of transgene expression in vivo. Nat Biotechnol 2001; 19: 838-842.
16. Le LP et al. Fluorescently labeled adenovirus with pIX-EGFP for vector detection. Mol Imaging 2004; 3: 105-116.
17. Dmitriev I et al. An adenovirus vector with genetically modified fibers demonstrates expanded tropism via utilization of a coxsackievirus and adenovirus receptor-independent cell entry mechanism. J Virol 1998; 72: 9706-9713.
18. Belousova N, Krendelchtchikova V, Curiel DT, Krasnykh V. Modulation of adenovirus vector tropism via incorporation of polypeptide ligands into the fiber protein. J Virol 2002; 76: 8621-8631.
19. Wu H et al. Construction and characterization of adenovirus serotype 5 packaged by serotype 3 hexon. J Virol 2002; 76: 12775-12782.
20. Dmitriev IP, Kashentseva EA, Curiel DT. Engineering of adenovirus vectors containing heterologous peptide sequences in the C terminus of capsid protein IX. J Virol 2002; 76: 6893-6899.
21. Schraa AJ et al. Targeting of RGD-modified proteins to tumor vasculature: a pharmacokinetic and cellular distribution study. Int J Cancer 2002; 102: 469-475.
22. Satchi-Fainaro R et al. Targeting angiogenesis with a conjugate of HPMA copolymer and TNP-470. Nat Med 2004; 10: 255-261.
23. Greenberger S et al. Transcription-controlled gene therapy against tumor angiogenesis. J Clin Invest 2004; 113: 1017-1024.
24. Braciak TA et al. Construction of recombinant human type 5 adenoviruses expressing rodent IL-6 genes. An approach to investigate in vivo cytokine function. J Immunol 1993; 151: 5145-5153.
25. Miller G et al. Natural killer cell depletion confounds the antitumor mechanism of endogenous IL-12 overexpression. Int J Cancer 2004; 110: 395-402.
26. Deng JC, Tateda K, Zeng X, Standiford TJ. Transient transgenic expression of gamma interferon promotes Legionella pneumophila clearance in immunocompetent hosts. Infect Immun 2001; 69: 6382-6390.
27. He TC et al. A simplified system for generating recombinant adenoviruses. Proc Natl Acad Sci USA 1998; 95: 2509-2514.
28. Maizel Jr JV, White DO, Scharff MD. The polypeptides of adenovirus. I. Evidence for multiple protein components in the virion and a comparison of types 2, 7A, and 12. Virology 1968; 36: 115-125.
29. Nicklin SA et al. Analysis of cell-specific promoters for viral gene therapy targeted at the vascular endothelium. Hypertension 2001; 38: 65-70.
30. Conry RM et al. Immune response to a carcinoembryonic antigen polynucleotide vaccine. Cancer Res 1994; 54: 1164-1168.
31. Raben D et al. Enhancement of radiolabeled antibody binding and tumor localization through adenoviral transduction of the human carcinoembryonic antigen gene. Gene Therapy 1996; 3: 567-580.
32. Zhu ZB et al. Transport across a polarized monolayer of Caco-2 cells by transferrin receptor-mediated adenovirus transcytosis. Virology 2004; 325: 116-128.
33. Reynolds PN. Delivery of DNA to pulmonary endothelium. using adenoviral vectors. In: Heiser WC (ed) Gene Delivery to Mammalian Cells: Methods and Protocols. Humana Press: Totowa, NJ, USA, 2002, pp 69-90.